Adult Stem Cell Trial At Barts And London NHS Trust24 September 2008
(REGENERATE – IHD & REGENERATE – DCM)
Randomised Control Trial To Compare The Effects Of G-CSF And Autologous Bone Marrow Progenitor Cells Infusion On Quality Of Life And Left Ventricular Function In Patients With Heart Failure Secondary to Ischaemic Heart Disease
Randomised Controlled Trial To Compare The Effects Of G-CSF And Autologous Bone Marrow Progenitor Cells On Quality Of Life And Left Ventricular Function In Patients With Idiopathic Dilated Cardiomyopathy
Pluripotential Primitive Cells, Cardiac Repair and Regeneration
The heart is an organ of limited regenerative capacity and as such has insufficient potential to repair itself. The response to injury comprises adaptive mechanisms such as the opening up of collateral vessels, the hypertrophy of pre-existing cardiomyocytes and the scar formation by stimulation of fibroblasts (remodelling). Recent work that has analysed atrial tissue from sex mismatched heart transplant recipients has demonstrated that primitive cells can migrate into the transplanted heart from the recipient in small numbers 1. Histological examination has shown that these cells express surface markers demonstrating differentiation into various cell types (cardiomyocytes, endothelial cells and vascular smooth muscle cells) had taken place. This important observation implies that there may be a background level of cellular renewal by engraftment and differentiation of primitive cells that is insufficient to deal with significant levels of myocyte damage. The most likely source of these primitive cells is the bone marrow. Experiments in mice have demonstrated homing and engraftment of labelled bone marrow derived progenitor cells to the site of myocardial infarction. As before, histological examination demonstrated that these labelled cells had undergone a process of differentiation and expressed cardiomyocyte surface markers.
Since it had previously been shown that direct injection of bone marrow progenitor cells into the perinfarct zone in a mouse model of myocardial infarction lead to a repopulation of myocytes and improvement in left ventricular function 2 the concept that the bone marrow may provide a source of primitive cells capable of repairing the damaged heart evolved. Orlic and co-workers 3 were able to demonstrate that primitive cells could be mobilised from the bone marrow in a mouse model of myocardial infarction using a combination of the cytokines stem cell factor (SCF) and granulocyte colony stimulating factor (G-CSF). Treatment with these cytokines for 5 days prior to coronary artery ligation and for 3 days afterwards resulted in reduction in mortality, infarct size, magnitude of cavity dilatation and diastolic stress at 27 days post-infarct compared with saline-injected animals. Left ventricular ejection fraction, as measured by echocardiography, was greater in cytokine-treated animals compared with controls.
Stem Cell Therapy to Treat Cardiovascular Disease in Man
Several groups have published preliminary data demonstrating the safety and efficacy of stem cell administration to treat cardiovascular disorders in man. Autologous bone marrow derived progenitor cells have been administered to patients undergoing acute myocardial infarction by direct intracoronary and intracardiac injection 4-6. Although the published data is for short periods of follow-up, all studies report some improvement in indices of cardiac function or symptoms and no immediate adverse events. Patients with heart failure secondary to ischaemic heart disease have also been shown to derive benefits in cardiac performance and symptoms when treated with autologous bone marrow derived progenitor cells 7-9.
To date, one study has reported on the use of G-CSF to treat patients with heart failure secondary to ischaemic heart disease 10. At this moment in time the study is recruiting but reports no adverse events in the group of patients treated with G-CSF. Animal work however suggests that although G-CSF can mobilise bone marrow derived progenitor cells, these cells may require a separate stimulus to home and engraft at the site of myocardial damage 11. Work by Professor Zeiher’s group in Frankfurt, who have now administered intracoronary bone marrow derived progenitor cells to approximately 200 patients with ischaemic heart disease, suggest that a period of myocardial ischaemia is required for homing and engraftment of the stem cells to occur (personal communication Prof A Zeiher, University of Frankfurt). The ischaemia induced by balloon inflation in the proximal coronary artery at the time of stem cell infusion (necessary to prevent spillage into the peripheral circulation) would appear to be sufficient for homing and engraftment without leading to a rise in cardiac enzymes that would suggest myocardial damage.
To date, two direct methods of introducing stem cells to the myocardium have been used in man: direct intracoronary injection 5 and direct intramyocardial injection 12. Whilst intracoronary injection has the advantage of being less invasive than direct intramyocardial injection, it has the disadvantage that patients with coronary artery occlusion are thus unable to receive stem cells directly to the site of injury unless the occluded artery supplying that region can be reopened. Such procedures to open chronically occluded coronary arteries are technically complicated and associated with a low long-term patency. Direct intramyocardial injection has recently been shown to be feasible using a percutaneous technique and non-fluoroscopic mapping system (NOGA) 12. Therefore, given the high proportion of patient that will have coronary artery occlusion as a result of their ischaemic heart disease, the technique of direct intramyocardial stem cell delivery has been included as an arm of the interventional part of this study.
The aim of this project is to investigate whether G-CSF, alone or in combination with direct intracoronary autologous bone marrow derived progenitor cell injection, is capable of improving symptoms and cardiac function in patients with heart failure secondary to ischaemic heart disease. The design of the study seeks to determine whether a significant improvement in cardiac function and symptoms can be achieved by the relatively non-invasive procedure of G-CSF administration or whether an invasive approach requiring direct intracoronary injection provides the optimal improvement. Only symptomatic patients with no further treatment options will be considered for this study.
There is a unique opportunity to refer symptomatic heart failure patients caused by Idiopathic dilated cardiomyopathy (DCM) or Ischaemic heart disease (IHD) who have no further treatment options, to participate in these clinical trials. If you think you have any patients who may be suitable for such studies please contact the Cardiac Research team at The London Chest Hospital.
Table 1 Flow chart of REGENERATE studies
Patients will be randomised to either non-intervention or intervention.
Follow-up at 6 months and 1 year
Dr. Anthony Mathur (referrals)
Email the team at REGENERATE@bartsandthelondon.nhs.uk or telephone 020 8983 2213
1. Quaini F, Urbanek K, Beltrami AP, et al. Chimerism of the transplanted heart. N.Engl.J Med. 2002; 346(1):5-15.
2. Orlic D, Kajstura J, Chimenti S, Bodine DM, Leri A, Anversa P. Transplanted adult bone marrow cells repair myocardial infarcts in mice. Ann N Y Acad Sci 2001; 938:221-9; discussion 229-30.
3. Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A 2001;98(18):10344-9.
4. Strauer BE, Brehm M, Zeus T, et al. [Intracoronary, human autologous stem cell transplantation for myocardial regeneration following myocardial infarction]. Dtsch Med Wochenschr 2001;126(34-35):932-8.
5. Assmus B, Schachinger V, Teupe C, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 2002; 106(24):3009-3017.
6. Stamm C, Westphal B, Kleine HD, et al. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 2003;361(9351):45-46.
7. Perin EC, Dohmann HF, Borojevic R, et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 2003;107(18):2294-2302.
8. Tse HF, Kwong YL, Chan JK, Lo G, Ho CL, Lau CP. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet 2003;361(9351):47-49.
9. Hamano K, Nishida M, Hirata K, et al. Local implantation of autologous bone marrow cells for therapeutic angiogenesis in patients with ischemic heart disease: clinical trial and preliminary results. Jpn Circ J 2001; 65(9):845-7.
10. Belenkov Iu N, Ageev FT, Mareev V, Savchenko VG. [Mobilization of bone marrow stem cells in the management of patients with heart failure. Protocol and first results of ROT FRONT trial]. Kardiologiia 2003; 43(3):7-12.
11. Askari AT, Unzek S, Popovic ZB, et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 2003;362(9385):697-703.
12. Smits PC, van Geuns RJ, Poldermans D, et al. Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up. J Am Coll Cardiol 2003; 42(12):2063-9.
To download a pdf version of this article, please click here.
Original script written by Dr Anthony Mathur, London Chest Hospital
Number of hits: 7624 Add Comments